Abstract
The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Current Pharmaceutical Design
Title: Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Volume: 16 Issue: 34
Author(s): Andreja Trpkovic, Edith Stokic, Djordje Radak, Zoran Gluvic, Mohamed Haidara, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Abstract: The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Export Options
About this article
Cite this article as:
Trpkovic Andreja, Stokic Edith, Radak Djordje, Gluvic Zoran, Haidara Mohamed, P. Mikhailidis Dimitri and R. Isenovic Esma, Chronic Hepatitis C, Insulin Resistance and Vascular Disease, Current Pharmaceutical Design 2010; 16 (34) . https://dx.doi.org/10.2174/138161210794455067
DOI https://dx.doi.org/10.2174/138161210794455067 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bidirectional Nature of Cardiovascular and Kidney Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design Quantitative Color Doppler Ultrasonography Measurement of Thyroid Blood Flow in Patients with Graves’ Disease
Current Medical Imaging Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes
Current Neurovascular Research Inflammatory Cytokines and Cardiovascular Disease
Current Drug Targets - Inflammation & Allergy Endocrine Therapies and QTc Prolongation
Current Drug Safety Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Targeting the Platelet Integrin GPIIb/IIIa
Current Pharmaceutical Design Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model
Current Drug Delivery The Association Between HIV/AIDS During Pregnancy and Fetal Growth Parameters in Florida: A Population Based Study
Current HIV Research Dietary Fat and Hypertension: A Novel Approach Through the Proteolytic Regulatory Enzymes of the Renin-Angiotensin-System
Cardiovascular & Hematological Agents in Medicinal Chemistry Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Novel Fibrinogen Receptor Antagonists - RGDF Mimetics, 4-(1,2,3,4- tetrahydro-isoquinoline-7-yl)amino-4-oxo-butyric Acid Derivatives
Medicinal Chemistry Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Endoglin-Targeted Cancer Therapy
Current Drug Delivery The Control of Male Sexual Responses
Current Pharmaceutical Design